SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending intensely after a strong earnings report highlighted by surging AI chip revenue, a new OpenAI partnership, and significantly raised future guidance alongside a substantial share repurchase program. This has ignited strong bullish sentiment on its foundational role in the accelerating AI infrastructure, while some community members debate valuation and anticipate profit-taking.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is experiencing a surge following reports of early talks with OpenAI for a potential partnership to integrate advertising into ChatGPT, which the community views as a significant new revenue opportunity in the AI space. This development, combined with a massive $148 million insider share purchase by the CEO, is sparking widespread discussion about a potential short squeeze and a turnaround for the recently oversold stock.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors digest its Q4 earnings and reiterated 2026 guidance, with community debate centering on conservative future projections and management's communication regarding the TDAPA transition and ongoing high short interest. Many view the newly authorized $75 million share repurchase program, alongside upcoming Rezzayo Phase 3 data, as key catalysts for a stock perceived by some to be significantly undervalued.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending after reporting strong quarterly results that surpassed analyst expectations with significant revenue growth, alongside optimistic guidance for future years. The community is actively discussing its valuation and market potential in high-performance battery applications for drones, aviation, and electric vehicles, often highlighting its tangible progress compared to competitors.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is seeing significant interest following robust Q4 earnings, strong FY26 revenue guidance, and new defense contracts for missile propulsion and advanced multi-domain swarming autonomy, fueling community discussions about its potential as a leading defense AI player amidst notable short interest.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com's recent quarterly earnings, which showed missed revenue and a net loss amid aggressive competition and investments in new ventures like food delivery, are fueling investor frustration over its profitability and stock performance, though some highlight its robust cash position and deep undervaluation as a long-term opportunity in the challenging Chinese e-commerce market.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending following its Q4 earnings, where initial confusion over EPS figures has been clarified to an inline beat, accompanied by strong revenue growth and record customer assets. While bulls highlight global expansion and new AI tools, the community remains divided over concerns regarding aggressive growth-related spending, ongoing share dilution, and the stock's persistent underperformance against a backdrop of positive operational metrics.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending after releasing positive Phase 2 data for HLP004, showing significant efficacy in generalized anxiety disorder patients who remained symptomatic despite existing treatments. This promising clinical outcome has sparked intense community discussion, as the stock experienced a notable decline, leading to debate over its current valuation and the broader psychedelic sector's potential.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending after reporting significantly missed Q4 revenue and widening losses, leading to widespread community frustration over its multi-billion dollar market cap versus negligible sales. Many are debating if the quantum computing pure-play is an overvalued "science project" or a long-term strategic bet, with some anticipating further drops and others eyeing a short squeeze despite the poor financials.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is trending following a Q4 earnings beat that was overshadowed by cautious Q1 guidance, sparking a divided community discussion on its near-term growth trajectory. Investors are weighing the immediate outlook against the company's emphasized long-term opportunity in securing AI agents within the evolving cybersecurity landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

Equity

Cormedix Earnings Review: Q4 Summary

Royce & Associates LP Buys New Stake in CorMedix Inc $CRMD

Royce & Associates LP purchased a new stake in CorMedix Inc (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission...

CorMedix (CRMD) Projected to Post Quarterly Earnings on Thursday

CorMedix (NASDAQ:CRMD) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...

ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of +17.32% and +6.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and +0.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?

CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.

CorMedix Inc (NASDAQ:CRMD) Receives Consensus Rating of "Moderate Buy" from Analysts

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock...

CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?

CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.

$CRMD Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.18 down -18.18% YoY
• Reported revenue of $128.62M up 312.10% YoY
• CorMedix reiterates its 2026 guidance, projecting net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M, reflecting its strategic outlook.

Stocktwits

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.18 down -18.18% YoY
• Reported revenue of $128.62M up 312.10% YoY
• CorMedix reiterates its 2026 guidance, projecting net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M, reflecting its strategic outlook.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits Polls

Traders are baffled as the stock dives despite solid Q4 and FY2025 results and reiterated 2026 guidance, questioning market reaction.

Despite robust cash, EBITDA, and hyper-growth, many believe the stock trades at a significant 50-75% discount compared to biotech peers.

Investors express strong dissatisfaction with current management, citing poor communication and a failure to convey the company's value, impacting stock performance.

Uncertainty surrounds the looming July 1 TDAPA transition, with investors demanding more clarity on its long-term impact on revenue and pricing beyond 2026.

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest CRMD News

CRMDCorMedix Inc